Development of a Pan-Cancer 15 Gene Expression Signature to Detect a Subgroup Driven by MAPK Signalling
Download Almac Diagnostic Services Poster Presentation on ‘Development of a Pan-Cancer 15 Gene Expression Signature to Detect a Subgroup Driven by MAPK Signalling’.
Conclusion:
- A 15 gene signature has been developed from formalin fixed paraffin embedded samples to detect a molecular subgroup driven by MAPK/EMT signalling across multiple diseases .
- This assay predicts sensitivity to MEK inhibitors in preclinical model systems.
- Further work aims to validate the EMT assay in clinical samples from patients treated with a MEK or EMT inhibitor.
- This assay may be helpful for clinical trial enrichment to select patients that are likely to benefit from MAPK or EMT targeted therapies.
